[go: up one dir, main page]

EP4064861A4 - PHARMACEUTICAL MICRONUTRIENT COMPOSITION AND USE THEREOF FOR SIMULTANEOUSLY INHIBITING MULTIPLE CELLULAR INFECTION MECHANISMS CAUSED BY CORONAVIRUS, ITS VARIANTS AND MUTANTS - Google Patents

PHARMACEUTICAL MICRONUTRIENT COMPOSITION AND USE THEREOF FOR SIMULTANEOUSLY INHIBITING MULTIPLE CELLULAR INFECTION MECHANISMS CAUSED BY CORONAVIRUS, ITS VARIANTS AND MUTANTS Download PDF

Info

Publication number
EP4064861A4
EP4064861A4 EP21801817.4A EP21801817A EP4064861A4 EP 4064861 A4 EP4064861 A4 EP 4064861A4 EP 21801817 A EP21801817 A EP 21801817A EP 4064861 A4 EP4064861 A4 EP 4064861A4
Authority
EP
European Patent Office
Prior art keywords
coronavirus
mutants
variants
pharmaceutical
multiple cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21801817.4A
Other languages
German (de)
French (fr)
Other versions
EP4064861A1 (en
Inventor
Aleksandra Niedzwiecki
Anna Goc
Vadimo IVANOV
Matthias W. Rath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2021/024182 external-priority patent/WO2022173456A1/en
Publication of EP4064861A1 publication Critical patent/EP4064861A1/en
Publication of EP4064861A4 publication Critical patent/EP4064861A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP21801817.4A 2021-02-15 2021-03-25 PHARMACEUTICAL MICRONUTRIENT COMPOSITION AND USE THEREOF FOR SIMULTANEOUSLY INHIBITING MULTIPLE CELLULAR INFECTION MECHANISMS CAUSED BY CORONAVIRUS, ITS VARIANTS AND MUTANTS Pending EP4064861A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149633P 2021-02-15 2021-02-15
PCT/US2021/024182 WO2022173456A1 (en) 2021-02-15 2021-03-25 A pharmaceutical micronutrient composition and its use to simultaneously inhibit multiple cellular mechanisms of infectivity caused by coronavirus, its variants and mutants

Publications (2)

Publication Number Publication Date
EP4064861A1 EP4064861A1 (en) 2022-10-05
EP4064861A4 true EP4064861A4 (en) 2023-10-18

Family

ID=80001854

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21801817.4A Pending EP4064861A4 (en) 2021-02-15 2021-03-25 PHARMACEUTICAL MICRONUTRIENT COMPOSITION AND USE THEREOF FOR SIMULTANEOUSLY INHIBITING MULTIPLE CELLULAR INFECTION MECHANISMS CAUSED BY CORONAVIRUS, ITS VARIANTS AND MUTANTS

Country Status (2)

Country Link
EP (1) EP4064861A4 (en)
DE (1) DE212021000181U1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022034549A1 (en) * 2020-08-14 2022-02-17 Rath Matthias W Micronutrient combination to inhibit coronavirus cell infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022034549A1 (en) * 2020-08-14 2022-02-17 Rath Matthias W Micronutrient combination to inhibit coronavirus cell infection

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GOC ET AL: "Micronutrient combination inhibits two key steps of coronavirus (SARS-CoV-2) infection: viral binding to ACE2 receptor, and the receptor's cellular expression", JOURNAL OF CELLULAR MEDICINE AND NATURAL HEALTH, 14 August 2020 (2020-08-14), pages 1 - 7, XP093079761, Retrieved from the Internet <URL:https://jcmnh.org/wp-content/uploads/2021/07/GOC-251020.pdf> [retrieved on 20230907] *
HASLBERGER ALEXANDER ET AL: "Mechanisms of selected functional foods against viral infections with a view on COVID-19: Mini review", vol. 10, no. 5, 11 May 2020 (2020-05-11), pages 195, XP055784899, ISSN: 2378-7007, Retrieved from the Internet <URL:https://www.ffhdj.com/index.php/ffhd/article/viewFile/707/1259> DOI: 10.31989/ffhd.v10i5.707 *
IVANOV VADIM ET AL: "Inhibition of ACE2 Expression by Ascorbic Acid Alone and its Combinations with Other Natural Compounds", INFECTIOUS DISEASES: RESEARCH AND TREATMENT, vol. 14, 1 January 2021 (2021-01-01), XP093079770, ISSN: 1178-6337, DOI: 10.1177/1178633721994605 *
IVANOV VADIM: "Effective and safe global public health strategy to fight the COVID-19 pandemic: Specific micronutrient combination inhibits Coronavirus cell-entry receptor (ACE2) expression", JOURNAL OF CELLULAR MEDICINE AND NATURAL HEALTH, 2 July 2020 (2020-07-02), pages 1 - 17, XP093079762, Retrieved from the Internet <URL:https://jcmnh.org/2020/07/02/effective-and-safe-global-public-health-strategy-to-fight-the-covid-19-pandemic-specific-micronutrient-composition-inhibits-coronavirus-cell-entry-receptor-ace2-expression/#1594134135991-3c34ec37-3486> [retrieved on 20230907] *
KHAN NABAB ET AL: "Possible Therapeutic Use of Natural Compounds Against COVID-19", JOURNAL OF CELLULAR SIGNALING, 1 January 2021 (2021-01-01), pages 63 - 79, XP093069458, Retrieved from the Internet <URL:https://www.scientificarchives.com/public/assets/articles/article-pdf-1664354169-490.pdf> [retrieved on 20230801] *
KHANNA KANIKA ET AL: "Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle", PHYTOMEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 85, 3 October 2020 (2020-10-03), XP086537990, ISSN: 0944-7113, [retrieved on 20201003], DOI: 10.1016/J.PHYMED.2020.153361 *
MHATRE SUSMIT ET AL: "Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review", PHYTOMEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 85, 17 July 2020 (2020-07-17), XP086537618, ISSN: 0944-7113, [retrieved on 20200717], DOI: 10.1016/J.PHYMED.2020.153286 *
See also references of WO2022173456A1 *

Also Published As

Publication number Publication date
EP4064861A1 (en) 2022-10-05
DE212021000181U1 (en) 2022-01-11

Similar Documents

Publication Publication Date Title
EP4417606A4 (en) New pyrimidopyridine compound, pharmaceutical composition thereof and use thereof
EP3964516A4 (en) OXAAZACHUINAZOLINE-7( 8H)-KETONE COMPOUND, PROCESS FOR ITS PRODUCTION AND ITS PHARMACEUTICAL APPLICATION
EP4209513A4 (en) BISPECIFIC ANTI-VEGF-ANTI-PD-L1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF
CL2007003341A1 (en) COMPOUNDS DERIVED FROM IMIDAZOTRIAZINAS; PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF CANCER, ARTEROSCLEROSIS AND CARDIOVASCULAR DISEASES BETWEEN OTHERS.
EP2124921A4 (en) Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
CL2007002686A1 (en) COMPOUNDS DERIVED FROM 2H-ISOQUINOLIN-1-ONA AND 3H-QUINAZOLIN-4-ONA, RHO KINASE INHIBITORS; AND PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE OR AFFECTION.
BRPI0813499B8 (en) pyrimidine compounds carboxamides useful as raf kinase inhibitors, pharmaceutical composition comprising the same and method of preparation thereof
NO20084923L (en) N- (2-thiazolyl) -amide derivatives as GSK-3 inhibitors
BRPI1013984A2 (en) compound, pharmaceutical composition, method for treating or prophylaxis of a disease or condition, and use of a compound.
EA200802324A1 (en) NEW FORM FOR THE INTRODUCTION OF THE RACECADOTRIAL
BRPI0815591A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR TREATING A DISEASE, CONDITION OR DISTURBANCE.
BRPI0513909A (en) multi-layer pharmaceutical tablet for controlled release of active ingredients with highly ph-dependent solubility
EP4095158A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING ANTI-BTLA ANTIBODIES AND USE THEREOF
CR10092A (en) NEW SUBSTITUTED ACICLIC FUROPIRIMIDINE DERIVATIVES AND THEIR USE
EP4410837A4 (en) BISPECIFIC ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
CL2007003825A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A HUMANIZED HUMANIZED MONOCLONAL ANTIBODY ANTI-ANTIGEN OF HUMAN LEUCOCITARY DIFFERENTIATION CD6; AND ITS USE FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTARY LEUKEMIA B.
EP4064861A4 (en) PHARMACEUTICAL MICRONUTRIENT COMPOSITION AND USE THEREOF FOR SIMULTANEOUSLY INHIBITING MULTIPLE CELLULAR INFECTION MECHANISMS CAUSED BY CORONAVIRUS, ITS VARIANTS AND MUTANTS
EP1827446A4 (en) Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
EP4201941A4 (en) PYRAZOLBORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF
ATE471930T1 (en) 3-AMINOCARBAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHOD FOR THE PRODUCTION THEREOF
EP4393512A4 (en) COMPOSITION FOR MEDICINAL TABLET, MEDICINAL TABLET MANUFACTURED THEREFROM AND MANUFACTURING METHOD THEREFOR
DE602006019961D1 (en) CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERROBABLE TABLETS CONTAINING ESCITALOPRAMBASE
DK1718340T3 (en) New effector conjugates, processes for their preparation and their pharmaceutical use
NO20031219D0 (en) Novel Compounds Derived from Quinazoline, Methods for their Preparation, and Pharmaceutical Compositions Containing Them
UY29358A1 (en) THIAZOLIDINONES, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20230920

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20230914BHEP

Ipc: A61P 31/12 20060101ALI20230914BHEP

Ipc: A61K 36/82 20060101ALI20230914BHEP

Ipc: A61K 36/9066 20060101ALI20230914BHEP

Ipc: A61K 36/31 20060101ALI20230914BHEP

Ipc: A61K 31/7048 20060101ALI20230914BHEP

Ipc: A61K 31/375 20060101ALI20230914BHEP

Ipc: A61K 31/366 20060101ALI20230914BHEP

Ipc: A61K 31/352 20060101ALI20230914BHEP

Ipc: A61K 31/198 20060101ALI20230914BHEP

Ipc: A61K 31/12 20060101ALI20230914BHEP

Ipc: A61K 31/05 20060101ALI20230914BHEP

Ipc: A23L 33/15 20160101ALI20230914BHEP

Ipc: A23L 33/12 20160101ALI20230914BHEP

Ipc: A23L 33/105 20160101ALI20230914BHEP

Ipc: A23L 33/10 20160101AFI20230914BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240528